EP 4136090 A1 20230222 - CRYSTALLINE RET INHIBITOR
Title (en)
CRYSTALLINE RET INHIBITOR
Title (de)
KRISTALLINER RET-HEMMER
Title (fr)
INHIBITEUR CRISTALLIN DE RET
Publication
Application
Priority
- US 202063011701 P 20200417
- US 202163151354 P 20210219
- US 2021026611 W 20210409
Abstract (en)
[origin: WO2021211380A1] Provided herein is a crystalline form of selpercatinib useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders, and methods of making this crystalline form.
IPC 8 full level
C07D 519/00 (2006.01); A61K 31/497 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP IL KR)
A61K 31/4995 (2013.01 - KR); A61P 35/00 (2018.01 - EP IL KR); C07D 487/08 (2013.01 - KR); C07D 519/00 (2013.01 - EP IL); C07B 2200/13 (2013.01 - KR)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021211380 A1 20211021; AU 2021255488 A1 20221110; AU 2021255488 B2 20240530; BR 112022020446 A2 20221129; CA 3174316 A1 20211021; CL 2022002849 A1 20230616; CN 115916791 A 20230404; CO 2022014882 A2 20221031; CR 20220520 A 20221115; DO P2022000221 A 20230115; EC SP22080982 A 20230131; EP 4136090 A1 20230222; IL 297212 A 20221201; JP 2023522012 A 20230526; KR 20230002706 A 20230105; MX 2022012952 A 20230111; PE 20230388 A1 20230306; TW 202202501 A 20220116
DOCDB simple family (application)
US 2021026611 W 20210409; AU 2021255488 A 20210409; BR 112022020446 A 20210409; CA 3174316 A 20210409; CL 2022002849 A 20221014; CN 202180043101 A 20210409; CO 2022014882 A 20221019; CR 20220520 A 20210409; DO 2022000221 A 20221017; EC DI202280982 A 20221017; EP 21722702 A 20210409; IL 29721222 A 20221011; JP 2022562612 A 20210409; KR 20227039684 A 20210409; MX 2022012952 A 20210409; PE 2022002417 A 20210409; TW 110112512 A 20210407